{"schema_version":"secwatch.filing_event.v1","accession":"0000875320-24-000221","form_type":"8-K","ticker":"VRTX","cik":"0000875320","company_name":"VERTEX PHARMACEUTICALS INC / MA","filed_at":"2024-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.195953+00:00","generated_at":"2026-05-30T06:41:25.880256+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Vertex Q3 product revenue $2.77B (+12% YoY); raises FY guidance to $10.8-10.9B","bullets":["GAAP net income $1.0B; non-GAAP net income $1.1B; cash & securities $11.2B.","FY 2024 product revenue guidance raised to $10.8-10.9B from $10.65-10.85B.","PDUFA dates: vanzacaftor triple Jan 2, 2025; suzetrigine Jan 30, 2025; both Priority Review.","Three programs advanced to Phase 3: suzetrigine in DPN, povetacicept in IgAN, VX-880 in T1D.","CASGEVY revenue from first infused patient; 45 ATCs activated globally."],"urls":{"canonical":"https://secwatch.observer/filing/0000875320-24-000221","json":"https://secwatch.observer/filing/0000875320-24-000221.json","markdown":"https://secwatch.observer/filing/0000875320-24-000221.md","text":"https://secwatch.observer/filing/0000875320-24-000221.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000221/0000875320-24-000221-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000221/vrtx-20241104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T06:41:25.880256+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}